0001609410-16-000004.txt : 20160902
0001609410-16-000004.hdr.sgml : 20160902
20160902113906
ACCESSION NUMBER: 0001609410-16-000004
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20160902
DATE AS OF CHANGE: 20160902
EFFECTIVENESS DATE: 20160902
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: HEMISPHERX BIOPHARMA INC
CENTRAL INDEX KEY: 0000946644
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 520845822
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-270035
FILM NUMBER: 161867622
BUSINESS ADDRESS:
STREET 1: 1617 JFK BLVD, SUITE #500
STREET 2: ONE PENN CENTER
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
BUSINESS PHONE: 215-988-0080
MAIL ADDRESS:
STREET 1: 1617 JFK BLVD, SUITE #500
STREET 2: ONE PENN CENTER
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
D
1
primary_doc.xml
X0707
D
LIVE
0000946644
HEMISPHERX BIOPHARMA INC
1617 JFK BLVD, SUITE #500
ONE PENN CENTER
PHILADELPHIA
PA
PENNSYLVANIA
19103
215-988-0080
DELAWARE
None
None
Corporation
true
Thomas
K
Equels
1617 JFK Blvd
Philadelphia
PA
PENNSYLVANIA
19103
Executive Officer
Director
Adam
Pascale
1617 JFK Blvd
Philadelphia
PA
PENNSYLVANIA
19103
Executive Officer
David
Strayer
1617 JFK Blvd
Philadelphia
PA
PENNSYLVANIA
19103
Executive Officer
Wayne
Springate
1617 JFK Blvd
Philadelphia
PA
PENNSYLVANIA
19103
Executive Officer
William
Mitchell
1617 JFK Blvd
Philadelphia
PA
PENNSYLVANIA
19103
Director
Peter
W
Rodino
1617 JFK Blvd
Philadelphia
PA
PENNSYLVANIA
19103
Director
Stewart
Appelrouth
1617 JFK Blvd
Philadelphia
PA
PENNSYLVANIA
19103
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2016-08-30
false
true
false
6600
H.C. Wainwright & Co., LLC
375
None
None
430 Park Avenue
New York
NY
NEW YORK
10022
CA
CALIFORNIA
IL
ILLINOIS
NJ
NEW JERSEY
NY
NEW YORK
TX
TEXAS
false
33334
33334
0
Warrants herein sold to investors when investors purchased registered shares. $01 of the total $1.50 per share purchase price of securities allocated to purchase of private warrants referred to herein.
false
3
2333
true
0
represents same percentage of total commissions received for combination of public share and private warrant offering as set forth in item 13 above.
0
true
false
HEMISPHERX BIOPHARMA INC
Thomas K. Equels
Thomas K. Equels
President
2016-09-01